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The first step of the reaction catalyzed by the
homodimeric FabH from a dissociated fatty
acid synthase is acyl transfer from acyl-CoA
to an active site cysteine. We report that C1 to
C10 alkyl-CoA disulfides irreversibly inhibit
Escherichia coli FabH (ecFabH) and Myco-
bacterium tuberculosis FabH with relative effi-
ciencies that reflect these enzymes’ differential
acyl-group specificity. Crystallographic and
kinetic studies with MeSSCoA show rapid inhi-
bition of one monomer of ecFabH through
formation of a methyl disulfide conjugate with
this cysteine. Reaction of the second subunit
with either MeSSCoA or acetyl-CoA is much
slower. In the presence of malonyl-ACP, the
acylation rate of the second subunit is restored
to that of the native ecFabH. These observa-
tions suggest a catalyticmodel in which a struc-
turally disordered apo-ecFabH dimer orders on
binding either the first substrate, acetyl-CoA, or
the inhibitor MeSSCoA, and is restored to a dis-
ordered state on binding of malonyl-ACP.
INTRODUCTION
Fatty acid biosynthesis, an essential and universal pro-
cess for cell membrane generation and maintenance, is
carried out by two related but distinct de novo fatty acid
synthase (FAS) systems. Eukaryotes utilize a large multi-
functional protein with one or two polypeptides (type I
FAS system) [1–3], whereas the type II FAS system of
plants, prokaryotes, and protozoa is composed of dis-
crete monofunctional enzymes with activities that corre-
spond to the domains of the type I single-chain FAS
[4–6]. These significant differences in structure and orga-
nization of the type I and II FAS systems have distin-
guished the type II FAS enzymes as potential targets for
development of novel antibacterial and antiparasiticChemistry & Biology 14, 5agents that might have minimal side effects in humans
[7–9].
b-ketoacyl-ACP-synthase III (FabH) is a key enzyme in
bacterial fatty acid biosynthesis [4, 10], catalyzing the
committed step of the synthesis cycle. It initiates fatty
acid biosynthesis via a cysteine-mediated Claisen con-
densation reaction between malonyl-acyl carrier protein
(MACP) and an acyl-enzyme intermediate formed by initial
transacylation from the acyl-CoA primer to the active site
Cys112 [10]. CoA is released from the enzyme after trans-
acylation and replaced by MACP in the same binding
pocket. FabH then catalyzes the decarboxylation of
MACP, which reacts with the Cys112-bound acyl group
to form b-ketoacyl-ACP. This product is released, re-
duced to the corresponding acyl-ACP, and subsequently
elongated by other FAS condensing enzymes, including
FabB and FabF [11].
Of the known inhibitors of type II FAS enzymes, most
target enzymes other than FabH [12]. Cerulenin, thiolac-
tomycin, and phomallenic acids inhibit FabB and FabF.
Cerulenin forms a covalent adduct with the active site
cysteine of FabF [13, 14], while thiolactomycin acts as a
reversible inhibitor [8, 15, 16]. Recently, a number of new
inhibitor classes including indole-based inhibitors [17],
1,2-dithiole-3-ones [18], substituted thiazolidine-2-ones
[19], and benzoylaminobenzoic acid derivatives [20] that
target FabH have been discovered. These discoveries
have exploited the crystal structures of FabH from several
bacterial species [17, 21–29] and FabH assays amenable
to high-throughput screens [30].
The buried active site of FabH, consisting of the Cys112,
His244, and Asn274 catalytic triad, lies at the base of a nar-
row channel in which CoA binds. Crystal structures have
revealed that both the indole-based and benzoylamino-
benzoic acid FabH inhibitors bind in this channel [17,
20]. In the latter case, there also appears to be an interac-
tion of an inhibitor carboxylate with an active site Asn.
None of the inhibitors reported to date interacts with the
active site Cys112. This residue forms the acyl enzyme in-
termediate from the corresponding acyl-CoA substrate,
with release of CoA, and mutational analysis has shown
that this residue is critical for the condensing activity of
FabH [28, 29, 31, 32]. Selective chemical modification of13–524, May 2007 ª2007 Elsevier Ltd All rights reserved 513
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Alkyl-CoA Disulfides as FabH Mechanistic ProbesFigure 1. FabH Inhibition by Alkyl-CoA Disulfides
(A) Chemical structures of alkyl-CoA disulfides 1–5.
(B) Proposed mechanism of ecFabH inactivation by MeSSCoA (1). Cys112 of ecFabH forms a methyl disulfide conjugate upon incubation with MeSS-
CoA (1). The released CoA in the CoA binding channel may be retained or dissociated.Cys112 through formation of a mixed disulfide would thus
be expected to render the enzyme inactive.
FabHs from different bacterial species show different
substrate specificities for the acyl-CoA primer: the Es-
cherichia coli and Mycobacterium tuberculosis enzymes
(ecFabH and mtFabH) are specific for acetyl-CoA and
lauroyl-CoA, respectively [27, 33–37]. This specificity is
conferred by the size and shape of the acyl binding
pockets of these enzymes, which have been determined
from crystal structures. Because Cys112 sits at the junc-
ture of the CoA and acyl binding channels, inhibitors that
target this residue and contain structural components for
both the CoA and acyl binding channel might allow for
predictable selective inhibition of FabH enzymes.
Alkyl-CoA disulfides have been used previously as in-
hibitors and probes of choline acetyltransferase [38–43]
and spermidine/spermine acetyltransferases [44]. Currier
and Mautner demonstrated that methyl-CoA disulfide is
a potent competitive inhibitor of choline acetyltransferase,
and they proposed that the methyl-CoA disulfide (MeSS-
CoA) forms a tight complex with the enzyme without un-
dergoing chemical reaction [38, 39]. We hypothesized
that alkyl-CoA disulfides should act as FabH inhibitors
through formation of a mixed disulfide with the active
site Cys112, if the pKa of the cysteine-SH group is low
enough. The CoA group should provide a specificity deter-
minant directing the disulfide to the active site residue,
while the alkyl group would confer specificity for a FabH
enzyme.
As a test of our hypothesis, we have synthesized C1–C10
alkyl-CoA disulfides (Figure 1A) and shown that they give
predictable differential inhibition of ecFabH and mtFabH.514 Chemistry & Biology 14, 513–524, May 2007 ª2007 ElseviCrystal structures show formation of a covalent methyl
disulfide bond at one active site cysteine in the ecFabH di-
mer. These crystal structures in conjunction with a series
of kinetic binding and inhibition studies are consistent
with a catalytic model for FabH that involves structural
changes which accompany both substrate binding and
product release.
RESULTS AND DISCUSSION
Synthesis of Alkyl-CoA Disulfides 1–5
MeSSCoA (1) has previously been generated by reacting
the trilithium salt of CoA with an excess of S-methylmetha-
nethiosulfonate in water, with subsequent purification
using a Sephadex G-10 column [38, 39]. This procedure
proved problematic for synthesis of longer (C8 or C10)
alkyl-CoA disulfides due to solubility and purification
difficulties and was modified (see Figure S1 in the
Supplemental Data available with this article online) to
use the trihydrate of CoA and perform the coupling reac-
tion (with the corresponding S-alkylmethanethiosulfonate
reagent) in anhydrous methanol. When the reaction
reached completion (monitored by either reverse-phase
HPLC or TLC), the excess of the reagent was removed
by solvent extraction. The alkyl-CoA disulfides (1–5; Fig-
ure 1) were then purified on a C18 cartridge, and their
identity was confirmed by 1H NMR and high-resolution
mass spectrometry (HRMS) analysis (see Supplemental
Data). This modified procedure was robust and is likely
applicable for the synthesis of a wide range of alkyl-CoA
disulfides.er Ltd All rights reserved
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by Alkyl-CoA Disulfides 1–5
The effects of alkyl-CoA disulfides on the activity of ec-
FabH and mtFabH were initially studied by incubating
the inhibitors with FabH for 15 min at room temperature
and then using standard assay conditions described
previously [10, 29, 33, 45]. While MeSSCoA (1) inhibited
ecFabH (IC50 = 57.1 ± 4.5 mM), the disulfides with the
largest alkyl groups (4 and 5) showed no significant inhib-
itory activity at concentrations as high as 300 mM (Table 1).
Conversely, the longest-chain alkyl-CoA disulfides, octyl-
CoA (4) (IC50 30.1 ± 5.2 mM) and decyl-CoA (5) (IC50 1.2 ±
0.7 mM), were active against mtFabH, while 1 exhibited no
inhibition of mtFabH at 300 mM (Table 1). At these concen-
trations, there was no inhibition of mtFabH or ecFabH by
either butyl-CoA disulfide (2) with an intermediate-size
alkyl group or by the branched-chain sec-butyl-CoA
disulfide (3).
These specificities for the acyl-CoA disulfide inhibitors
parallel those for the acyl-CoA substrates of these
enzymes [24, 29, 35, 36, 46]. mtFabH reacts only with
long-chain (C10–C16) acyl-CoAs and has a long internal
acyl binding channel extending from the active site cyste-
ine [28]. In ecFabH, this channel is obstructed by Phe87
from the other subunit (which is a threonine in mtFabH),
leaving a pocket that can accept only acetyl- or pro-
pionyl-CoA substrates [24, 35, 36]. The initial hypothesis
that differential inhibition of FabH by alkyl-CoA disulfides
of varying alkyl chain length correlates with their acyl-
CoA substrate preferences is borne out and is consistent
with the alkyl group of the inhibitor binding in the FabH acyl
channel.
Cysteine Modification in ecFabH by MeSSCoA (1)
The alkyl-CoA disulfides were designed to target the
catalytically important Cys112 of FabH via a sulfhydryl-di-
sulfide exchange. We observed that ecFabH was inhibited
only by MeSSCoA (1) and that the presence of acetyl-CoA
provided protection against inhibition, consistent with
modification of the active site cysteine. An investigation
of the reversibility of this inhibition provided evidence









Methyl-CoA disulfide 1 57.1 ± 4.5 >300
Butyl-CoA disulfide 2 >300 >300
Sec-butyl-CoA disulfide 3 >300 >300
Octyl-CoA disulfide 4 >300 30.1 ± 5.2
Decyl-CoA disulfide 5 >300 1.2 ± 0.7
IC50, concentration of inhibitor at which 50% inhibition of
FabH activity is achieved.
a Inhibitors were preincubated with ecFabH for 15 min at room
temperature before assay.
b IC50 was determined without preincubation.Chemistry & Biology 14,that this modification was formation of a disulfide bond.
ecFabH with MeSSCoA (1) were incubated under con-
ditions that resulted in greater than 85% loss of enzyme
activity. No significant activity was recovered when the
inhibited protein was dialyzed (12 hr in 50 mM phosphate
buffer at pH 7.4 and 4C) or purified by gel filtration. In con-
trast, enzyme treated by reversible inhibitors regained full
activity under these conditions. Treatment of the inhibited
protein with 10 mM dithiothreitol for 30 min prior to dialysis
resulted in complete restoration of enzyme activity, con-
firming the presence of an active site cysteine disulfide
linkage. X-ray crystallographic studies (described below)
confirmed formation of this disulfide linkage and demon-
strate that it involves the methyl thiol (Figure 1B) and not
the CoA thiol.
Fluorimetric Studies of a Fast Reaction
between ecFabH and MeSSCoA (1)
Stopped-flow fluorimetry was employed to monitor the ini-
tial fast stages of interaction between ecFabH and MeSS-
CoA (1). As described below for the ecFabH-MeSSCoA
crystal structure and as also observed in the structure of
ecFabH-CoA complexes, the adenine ring of the CoA is
stacked between the indole side chain of Trp32 and the
guanidine group of Arg151, suggesting that changes in
Trp fluorescence emission might report interactions at
the ecFabH binding site. Indeed, fast mixing of the ec-
FabH (0.5 mM) with MeSSCoA (1) (150 mM) revealed an
initial fast decrease (t1/20.06 s) in Trp fluorescence emis-
sion followed by a relatively slow (t1/2 5 s) increase (Fig-
ure 2A). These changes are likely associated with binding
and inhibition of ecFabH, as BuSSCoA (2) does not inhibit
ecFabH (Table 1) and shows no effect on Trp fluorescence
(Figure 2A). Acetyl-CoA also did not cause a change in Trp
fluorescence (Figure 2A), indicating that there are dif-
ferences in the initial binding steps of inhibitor 1 and
substrate.
The changes in tryptophan fluorescence emission at
early times in the reaction were measured over a range
of MeSSCoA (1) concentrations (0–150 mM). The observed
rate constants (kobs) for both the decrease and increase in
fluorescence emission were determined by fitting a single
exponential equation to each corresponding trace as de-
scribed in Experimental Procedures. These rate constants
were then plotted versus concentration of MeSSCoA
(Figure 2B). The MeSSCoA (1) concentration dependence
of kobs for the fast decrease in Trp fluorescence demon-
strated saturation at concentrations higher than 100 mM
(Figure 2B), indicating a fast reversible binding (formation
of EI in Figure 3A) followed by a unimolecular transition
(formation of E-I in Figure 3A). Fitting a hyperbolic equa-
tion to the data obtained for the fast step of the reaction
gave the kinetic constants klim = 11.8 ± 1.4 s
1 and
K0.5 = 120 ± 30 mM. In contrast, the step detected by an
increase in Trp fluorescence emission was slower (kslow =
0.14 s1) and did not change significantly through the
whole range of concentrations of MeSSCoA (1) studied
(Figure 2B). This slow unimolecular step is tentatively
assigned to the E-I to E-I* conversion in Figure 3A.513–524, May 2007 ª2007 Elsevier Ltd All rights reserved 515
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of interaction of MeSSCoA (1) with ecFabH involve a re-
versible binding dependent on inhibitor concentration, fol-
lowed by a fast and then a slow step. The rates for these
changes indicate that under saturating concentrations of
MeSSCoA, formation of E-I* will be complete in less than
Figure 2. Fluorescence Kinetics for Interaction of ecFabH
with MeSSCoA, BuSSCoA, and Acetyl-CoA
(A) Time dependencies of changes in ecFabH (0.5 mM) Trp fluores-
cence (excitation 290 nm) emission is observed only with 150 mM
MeSSCoA (1) (darkest trace) and not with 150 mM acetyl-CoA or BuSS-
CoA (2) (other traces).
(B) The dependence of kobs for the fast (C) and slow (B) steps of the
reaction of ecFabH with MeSSCoA (1) on the concentration of the
inhibitor. Values of kobs for the fast (0–2 s) and slow (2–50 s) steps of
the reaction of ecFabH with MeSSCoA (1) were calculated by fitting
a single exponential equation to time traces of changes in the Trp fluo-
rescence emission observed for each step, as described in Experi-
mental Procedures.516 Chemistry & Biology 14, 513–524, May 2007 ª2007 Elsevi1 min. As described below, this E-I* retains 50% enzy-
matic activity.
ecFabH Undergoes Biphasic Inhibition
with MeSSCoA (1) and Biphasic Acylation
with Acetyl-CoA
Initial experiments showing that MeSSCoA (1) was the
only ecFabH inhibitor in the panel of alkyl-CoA disulfides
were carried out using a 15 min preincubation with
ecFabH. In the absence of this preincubation, MeSSCoA
was less effective (IC50 111.3 ± 4.2 mM), suggesting a
slow time-dependent inhibition step. A time course of
inactivation of ecFabH at varying concentrations of MeSS-
CoA (1) (1–50 mM) (Figure 4A) provided support for this hy-
pothesis. At inhibitor concentrations above 10 mM, there
was an initial fast partial inactivation of the enzyme fol-
lowed by a slower loss of activity (Figure 4A).
The fast step (ki1 > 0.023 s
1; Figure 3B) appears to be
dependent on MeSSCoA (1) concentration (Figure 4A) and
reaches a maximum of 50% inactivation (even with
400 mM MeSSCoA). The kinetic steps leading to E-I* (Fig-
ure 3A) revealed by fluorimetry reflect in part or whole the
steps which lead to this 50% inactivated complex (E-I0;
Figure 3B). Prolonged saturating conditions led to slow,
complete (more than 99%) loss of all enzymatic activity
(formation of E-I2 in Figure 3B). Kinetic constants for the
slow inhibition step, estimated by fitting a hyperbolic
equation to the data shown in Figure 4A, are ki2 = 2.5 ±
0.3 3 104 s1 and Ki = 37 ± 11 mM. This biphasic inhibi-
tion and 50% maximal inactivation in the fast step is con-
sistent with fast modification of the active site cysteine of
one subunit of the ecFabH dimer, followed by a much
slower modification of the corresponding residue in the
second subunit. As described below, crystal structures
show the MeS group substituted on only one of the two
subunits in the ecFabH dimer. The different modification
rates (there is more than a 90-fold difference between ki1
and ki2) might reflect changes resulting from modification
of one subunit or intrinsic differences between the two
subunits.
A similar biphasic process was seen for diacylation of
the ecFabH dimer by the acetyl-CoA substrate (Figure 4B).
We measured the rate of acylation of ecFabH with saturat-
ing concentrations of [14C]acetyl-CoA over a 10 min pe-
riod (Figure 4B). There was a fast monoacylation of ec-
FabH within 10 s of starting the reaction. Within 2 min,
the FabH dimer was almost completely radiolabeled by
two acetyl-CoA molecules (100% acylation). The assayFigure 3. Kinetic Analysis of Inhibition of
ecFabH by MeSSCoA
E, ecFabH; I, MeSSCoA.
(A) Steps observed by changes in Trp fluores-
cence emission of ecFabH.
(B) Steps observed by loss of ecFabH activity.
See text for details.er Ltd All rights reserved
Chemistry & Biology
Alkyl-CoA Disulfides as FabH Mechanistic Probesmethod permitted estimation of the sequential rates of ac-
ylation, as ka1 = 0.05 s
1 and ka2 = 0.005 s
1. These data
not only indicate that diacylation of ecFabH does occur,
consistent with an ecFabH acetyl-CoA crystal structure
which shows acylation of Cys112 in both subunits [25],
but also that the second acylation step is slower
(10-fold) than the first.
Parallels clearly exist between the biphasic acylation of
ecFabH with acetyl-CoA (Figure 4B) and biphasic inhibi-
tion with MeSSCoA (Figure 4A). The two-step process
is slower for the MeSSCoA inhibitor than for the acetyl-
CoA substrate (complete acylation occurs faster than
complete inhibition). This slow 50%–100% inhibition
step permitted determination of the acylation rate of the
second subunit of an ecFabH dimer already modified at
one active site with MeSSCoA. We treated the enzyme
with excess MeSSCoA for 2 min, at which time it retained
approximately 50% activity. As shown (Figure 4B), the rate
of acylation of this 50% inhibited ecFabH dimer was dra-
Figure 4. Biphasic Inhibition of ecFabH by MeSSCoA (1) and
Biphasic Acylation by [14C]Acetyl-CoA
(A) ecFabH (0.5 mM) was incubated with 1 (C), 3 (B), 5 (:), 10 (D), and
50 (-) mM MeSSCoA in 50 mM phosphate buffer (pH 7.4) at room tem-
perature. Aliquots (4 ml) were withdrawn from the incubation mixture at
the indicated times and activity of the enzyme was measured as de-
scribed in Experimental Procedures.
(B) Acylation of ecFabH was determined by reacting ecFabH (C) or the
50% active ecFabH-MeSSCoA complex (:) with [14C]acetyl-CoA
and measuring the amount of [14C]acetylated enzyme by liquid scintil-
lation counting.Chemistry & Biology 14,matically decreased (ka = 6.6 3 10
5 s1). The dramatic
decrease in either inhibitor modification or acylation of
the second active site by MeSSCoA and acetyl-CoA, re-
spectively, indicates that the biphasic processes do not
reflect intrinsic differences between the two subunits of
ecFabH, but rather differences caused by modification
of the first subunit. The rate of acylation of the 50% in-
hibited ecFabH (ka) is decreased approximately 1000-
fold and 100-fold relative to the two acylation steps for
the native ecFabH. However, in the presence of malonyl-
ACP, the enzyme retains 50% activity and the reaction
rate is greater than 0.016 s1, comparable to that of the
native ecFabH dimer (ka1 = 0.05 s
1). Because the dra-
matic decrease in acylation rate for ecFabH modified at
one active site cysteine by MeSSCoA is observed only in
the absence of malonyl-ACP, this observation suggests
that malonyl-ACP is reversing the asymmetry of subunit
catalytic activity imposed by prior inhibition or acylation
of the first active site.
Crystal Structures of the MeSSCoA-ecFabH
Complex
The structures of three complexes of MeSSCoA with
ecFabH confirmed the presence of an MeS group on the
active site cysteine of one (subunit A) of the two mono-
mers in each of the three crystal dimers. Two inhibition
complex structures were determined from preformed
crystals soaked in MeSSCoA at two different concentra-
tions (0.16 and 1.7 mM) of the inhibitor. Cocrystals were
also obtained by preincubation of the enzyme with 1 mM
MeSSCoA to form a complex, followed by crystallization
under high ionic strength conditions closely similar to
those used for the uninhibited enzyme. The crystal lattices
of these three complexes are isomorphous, and in all three
samples, the concentration of MeSSCoA was at the high
end of the range used for kinetic studies. The molar ex-
cess of inhibitor over protein was much higher in the soaks
than in the cocrystallization. Interpretation of the electron-
density maps was supported by careful iterative fitting and
adjustment of occupancies of the ligands, so that there
was minimal significant positive or negative residual elec-
tron density in the final mFo  dFc difference Fourier map.
Electron density for the SMe adduct on the side-chain
sulfur of the active site Cys112 is clear and unambiguous
in the A subunit of the two soaked structures. This obser-
vation confirms the identification of Cys112 as the target
residue for this inhibitor (Figure 5A). The SMe group in
these structures has an occupancy of 1.0 and 0.8 for the
high and low MeSSCoA concentration soaks, respec-
tively, and is sensitively reflected in the electron density
of the mFo  dFc difference Fourier maps from which it
was determined. The MeS group is oriented toward the
small hydrophobic pocket composed of the side chains
(given for subunit A) Phe87(B), Ala111(A), Leu142(A),
Phe157(A), Leu189(A), Leu205(A), and Gly306(A), which
has been inferred to constitute the acyl-group binding
site in ecFabH. The electron density for the MeS group
could not be fit by any of the known sulfoxides, consistent513–524, May 2007 ª2007 Elsevier Ltd All rights reserved 517
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Stereo figure showing electron density for (A) the CoA and MeS-Cys112 in the A subunit of the ecFabH-MeSSCoA (1) complex (0.16 mM) contoured at
a level of 0.9s, and (B) electron density of the corresponding site in the B subunit. Electron density of nearby groups is omitted for clarity.with all previous structures of ecFabH obtained under
these and similar conditions, which show Cys112 to be
in its reduced form. Like the structures of the soaked com-
plexes, the structure of the cocrystal complex has elec-
tron density only in the A site, albeit at lower occupancy
(0.3) and consequently less well defined, that can be fit518 Chemistry & Biology 14, 513–524, May 2007 ª2007 Elsevieby an SMe adduct on the Cys112 side chain. In contrast
to the soaked complexes, there is a conditionally occu-
pied solvent molecule site in the oxyanion hole of the coc-
rystal that overlaps the MeS density in this structure.
In the B subunit active site of all three ecFabH structures
determined, there is a single peak of electron density in ther Ltd All rights reserved
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a solvent ligand, either a water or possibly a hydroxide ion
[23, 25, 29], that is stabilized in its binding site by stereo-
chemical and charge similarity to the substrate acyl-group
oxyanion intermediate. This site is conditionally occupied
in the A subunit of the cocrystal structure, but there is no
evidence for any solvent in the oxyanion hole of the
high-occupancy methylthiolated A subunits in the two
soaked complexes.
Almost complete electron density for CoA is present in
the A subunit CoA channel (occupancies of 0.7 and 0.6
for high and low MeSSCoA concentration soaks, respec-
tively) for the two inhibitor soaked structures (Figure 5A),
with short breaks only at the C50-O50 bond of the ribose
and at the C5-C6 bond of the adenine ring. The side chains
of Trp32 and Arg151 are coplanar and separated to form
the stacked sandwich structure around the adenine ring
of the CoA that is observed in all other FabH-CoA com-
plexes [23, 25, 28]. The 30 phosphate of the CoA adenine
nucleotide in the A subunit forms an electrostatic interac-
tion with the guanidinium side chain of Arg40(B) from the B
subunit of a lattice-related dimer. The pyrophosphoryl
group of CoA makes multiple hydrogen-bond and electro-
static interactions: with the Asn210 side-chain amido
group, the Arg249 guanidinium side chain, and two sol-
vent molecules. The free terminal thiol group of CoA is ori-
ented toward Phe304, Ala246, and Val212 at the foot of
the CoA channel, but it and the pantetheinate group
make no polar interactions with the protein. In the cocrys-
tal complex structure, the very limited density in the CoA
channel cannot be fit by all or part of a CoA, and was mod-
eled as solvent water. Despite the absence of clearly or-
dered CoA in the A-site channel of the cocrystal complex
structure, the Trp32-Arg151 sandwich at the mouth is
open, indicating disordered occupancy of this site by the
CoA adenine. The B channel of all three structures shows
no connected density that could be fit by all or part of
a CoA, and the Trp32 and Arg151, which form the sand-
wich around the adenine of CoA, are disordered.
Comparison of the structures reported here with that re-
ported for ecFabH in complex (RCSB accession number
1HND) with CoA [21, 25] shows differences in conforma-
tion of the pantetheinate-mercaptoethylamine segments
of the cofactor. In the MeSSCoA-ecFabH structures, there
are no hydrogen bonds or polar interactions between CoA
and the enzyme, whereas in the ecFabH-CoA complex,
there was a single hydrogen bond between the amide
side chain of Asn247 and the pantetheinate peptide oxy-
gen proximal to the nucleotide end of CoA. Differences
in the CoA conformations in these two structures increase
down the channel toward the mercaptoethylamine termi-
nus of the cofactor near Cys112. The absence of any
strong bonding constraints on CoA within the binding
channel (as opposed to the mouth of the channel), also
noted in the complex of lauroyl-CoA with a C112A mutant
of mtFabH [28], is consistent with the variable and some-
times disordered structures reported for ligand bound
in this channel in the few determined FabH-cofactor
complex structures.Chemistry & Biology 14, 5The half-site occupancy observed in the crystal struc-
tures of the MeSSCoA inhibition complexes is consistent
with the biphasic inhibition of ecFabH by MeSSCoA in so-
lution. While different lattice environments of the two sub-
strate binding sites may contribute to different affinities for
inhibitor binding, formation of the MeSSCoA-ecFabH
complex cocrystals with the same half-site bias in subunit
occupancy implies that a significant population of half-oc-
cupied dimer ecFabH-inhibitor complexes exists in solu-
tion. A stabilizing lattice interaction is observed for the
CoA product of the inhibition complex in the A active
site where the Cys112 is methylthiolated, which likely ac-
counts for the retention of CoA product in that site. There
is no evidence for any significant MeS group substitution
on the Cys112 of the B-subunit active site at the high
concentrations of MeSSCoA used in these soaking exper-
iments, despite its completely unobstructed access to
solvent in the crystal lattice. It is also noteworthy that
soaking of ecFabH crystals over a 10-fold range of MeSS-
CoA produced an occupancy difference of 30% for the
MeS group in the two A sites with no evidence for any
binding of inhibitor in the B site, even at the higher inhibitor
concentration. This observation further supports an asym-
metry between the two sites of the ecFabH dimer both in
solution and in the crystal lattice, extending beyond the
different lattice environments of the two subunits.
In contrast to the differences in ligand and solvent occu-
pancy between the two subunits of the ecFabH crystal di-
mers, the conformations of these two crystallographically
nonequivalent subunits are virtually identical (rmsd =
0.44 A˚ for Ca atoms), except for minor variations in the
conformations of the loops from residues 196–201, which
lie in different lattice environments in the crystal and are
not proximal to the MeS or CoA ligands. There are no
side-chain conformational differences between the two
subunits of the dimer within the CoA binding channel.
A Model for FabH Catalysis
These studies demonstrate that MeSSCoA inhibits
ecFabH by transferring the MeS group to the active site
Cys112. This thiol-disulfide exchange process is distinct
from the acyl transfer process from acetyl-CoA in the
normal catalytic process, and differences between this
inhibitor and acetyl-CoA substrate are clearly observed
by fluorimetry. However, in both cases the active site thiol
is modified, the methyl group occupies the same acyl
binding pocket of the enzyme, and the rates of these
two processes on native ecFabH are comparable.
Solution and kinetic studies have also revealed that for
both the substrate and inhibitor, modification of the sec-
ond subunit proceeds at a much slower rate. There is
virtual identity in conformation between the polypeptide
chains of the two monomers of the ecFabH crystal struc-
tures reported herein, and also with those previously
reported [25], indicating that the slower rate of reaction
of the second subunit is not a reflection of a preexisting
structural difference between the two subunits. We ob-
serve that modification of one subunit by the MeSSCoA
inhibitor or acetyl-CoA results in differing effects on the13–524, May 2007 ª2007 Elsevier Ltd All rights reserved 519
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also show a highly ordered solvent in the oxyanion hole
of the B subunit of the ecFabH-inhibitor complex, which
must be displaced in order for the Cys112 of this subunit
to react with either ligand. These observations lead us to
propose that the slower rates for modification of this sec-
ond subunit are a result of changes induced by ligand
binding to the first subunit.
We suggest that the apo-ecFabH dimer in solution ex-
ists as a distribution of an ‘‘open’’ (partially disordered)
and a ‘‘closed’’ (fully ordered) form, the open form having
higher affinity for substrate and active site ligands. Binding
of a ligand to the partially ordered active site(s) of an open
dimer would induce formation of the closed form and shift
the distribution toward this conformational state. A previ-
ous crystal structure of apo-ecFabH (lacking either added
or adventitious ligands) in a tetragonal lattice (RCSB ac-
cession number 1HNK), with one monomer per asymmet-
ric unit, may represent the open form of apo-ecFabH [25].
In this structure, four loop regions constituting important
parts of the dimer interface and also the substrate binding
channel are disordered. In the ordered dimer structures of
ecFabH, both liganded and unliganded, these loops from
each monomer interact and are ordered. In addition, in this
tetragonal form of apo-ecFabH, the functional groups of
the active site are perturbed relative to their positions in
the ligand complexes, and were inferred to be in a catalyt-
ically impaired conformation [25]. These differences in
structure cannot be attributed to differences in lattice en-
vironment, which is the same for all tetragonal forms, both
unliganded and liganded, the latter of which are ordered in
these regions. The structural differences between the dis-
ordered tetragonal apo-ecFabH structure and the ordered
FabH structures extends to the solvent at the active site.
The disordered tetragonal apo-ecFabH structure has sol-
vent near but not in the oxyanion hole of the active site, its
distances from the hydrogen-bond donors of this site
being too long for stable hydrogen bonds.
It has been argued [25] that apo-ecFabH is intrinsically
disordered and does not achieve its functional confor-
mation until it has bound ligand. Because the flexible
loops interact intimately in the stable dimer, we further
argue that ordering of those loops through ligand binding
to one monomer would cooperatively induce ordering
of the counterpart loops in the other monomer, without a
requirement for ligand binding to the second monomer.
The slow step of interaction of MeSSCoA with ecFabH
we observe by fluorimetry could be such a ligand-induced
structural organization of the partially disordered apo-
ecFabH dimer.
Binding of a ligand at the active site of one of the two
partially disordered subunits in an open ecFabH dimer
would displace the solvent ligand from the oxyanion hole
of that subunit and result in a closed heterodimer with
only one active subunit cleared of solvent in its oxyanion
hole. Binding of a substrate or inhibitor ligand to the sec-
ond subunit would be hindered, both by its transition to
the lower affinity closed form and by retention of bound
solvent in its oxyanion hole. Ligand access to the active520 Chemistry & Biology 14, 513–524, May 2007 ª2007 Elsevsite of the second subunit in its closed form may still occur
through the CoA channel, but is likely to be much slower
than that with the open form. The kinetic evidence indi-
cates that access to the second subunit is reduced
more when the ligand binding in the first subunit is the
MeSSCoA inhibitor rather than acyl-CoA. Although there
are structural and reactivity differences between this sub-
strate and inhibitor, it is not clear which are critical in con-
ferring this difference in reactivity on the second active
site.
Our model for ecFabH catalysis thus involves ligand
binding to one subunit accompanied by modification of
the Cys122 active site and transition to a lower-affinity
closed heterodimer with differential catalytic competence
in the second subunit. The dramatic increase in acylation
rate of a closed ecFabH-MeSSCoA heterodimer with ace-
tyl-CoA which occurs in the presence of malonyl-ACP
suggests that this substrate causes a shift to a higher-af-
finity open heterodimer. In the normal ecFabH-catalyzed
process with acetyl-CoA, a shift to the open heterodimer
form by malonyl-ACP would facilitate both the subsequent
Claisen condensation and eventual product release and
restore the enzyme to its starting state.
SIGNIFICANCE
Previous studies of FabH enzymes have focused on
acyl-group substrate specificity, enzyme structure,
and mutational analysis to probe the role of three
catalytic residues [23, 25, 46, 47]. An understanding
of the kinetics of each catalytic step and any asso-
ciated conformational changes, as well as of the role
of each FabH subunit in these, remains largely unde-
termined. As a result, there are a number of observa-
tions regarding FabH and related enzymes that have
not been incorporated into the knowledge base of
this enzyme. These include the relatively poor activity
of FabH enzymes as transacylases (using ACP as op-
posed to malonyl-ACP as the second substrate), the
changes in relative acyl-CoA specificities of FabH en-
zymes conferred by noncognate malonyl-ACP sub-
strates, and acylation rates for condensing enzymes
which are slower than the observed overall catalytic
process [29, 31]. These studies support and expand
a previous proposal that apo-ecFabH exists in a par-
tially disordered form that becomes ordered on bind-
ing of substrate. Our results indicate that ecFabH
exists in a distribution of ‘‘open’’ and ‘‘closed’’ dimer
forms and that reaction of a substrate (acetyl-CoA)
or inhibitor (MeSSCoA) molecule with one subunit of
the dimer induces concomitant reduced affinity of
the second subunit for either ligand. This negative co-
operativity is observed only in the absence ofmalonyl-
ACP, indicating that binding of this second substrate
leads to a disordering of the ecFabH structure and
a shift in its distribution toward the open form. This
elaborated mechanism of FabH action may help to
rationalize previously inexplicable observations andier Ltd All rights reserved
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Malonyl-CoA, long-chain acyl-CoAs, imidazole, dithiothreitol (DTT),
and Ellman’s reagent (Sigma); coenzyme A trihydrate (Fluka);
reverse-phase thin-layer chromatography sheets (RP-TLC) with fluo-
rescent indicator at 254 nm (C18, RP-18 F254 s) (Merck); alkyl methane-
thiosulfonate (TRC Biomedical Research Chemicals); [1-14C]acetyl-
CoA (specific activity, 50 mCi/mmol) (Moravek Biochemicals);
[2-14C]malonyl-CoA (ARC-528, specific activity 55 mCi/mmol) (Ameri-
can Radiolabel); C18 cartridge (Supelco, Discovery DSC-18LT, bed wt




Prepared as reported earlier [48].
Methyl-CoA Disulfide 1
A solution of coenzyme A trihydrate (10 mg, 12.1 mmol) and methyl-
methanethiosulfonate (12 mg, 95.2 mmol, 8 equivalents) in anhydrous
methanol (0.7 ml) was stirred at room temperature for 3 hr under nitro-
gen. Reaction progress was monitored by HPLC (or RP-TLC) using UV
detection at 254 nm. After completion of the reaction, methanol was
removed in vacuo and the resulting solid residue was washed thor-
oughly with hexane (2 3 0.5 ml) and methylene chloride (2 3 0.5 ml)
to extract unreacted methylmethanethiosulfonate and other side prod-
ucts. The solid residue was dissolved in a minimal amount of methanol
and applied directly to a Supelco C18 cartridge preequilibrated with
water. The column was eluted (by applying positive pressure) with
a gradient of methanol in water (0%–100%), and the fractions contain-
ing the desired product (as determined by HPLC or RP-TLC) were
pooled and concentrated in vacuo to give the desired methyl-CoA di-
sulfide (1) (7 mg, 71%) as a white puffy solid: TLC Rf = 0.53 (C18 silica,
33% MeOH/H2O).
Alkyl-CoA Disulfides 2–5
The alkyl-CoA disulfides 2–5 were prepared as described above for
methyl-CoA disulfide 1 using the appropriate alkyl methanethio-
sulfonate.
Enzyme Expression and Purification
ecFabH and Streptomyces glaucescens FabD (sgFabD) proteins were
overexpressed in E. coli with an N-terminal polyhistidine tag and sub-
sequently purified by metal-chelation chromatography as described
previously [30, 37]. Purified mtFabH was prepared as described earlier
[28].
FabH Enzyme Assays
ecFabH assays were carried out using a standard coupled trichloro-
acetic acid precipitation assay, which determines the rate of formation
of radiolabeled 3-ketoacyl-ACP from malonyl-ACP and radiolabeled
acetyl-CoA [10, 33]. In this coupled assay, sgFabD is used to generate
the malonyl-ACP substrate (MACP) from malonyl-CoA and ACP [45].
The mtFabH assay was a modification of an assay procedure used
by Brown et al. [29] substituting malonyl-CoA for MACP. A typical
20 ml assay consisted of 12.5 mM lauroyl-CoA, 12.5–50 nCi [2-14C]-
malonyl-CoA (specific activity 55 mCi/mmol) in 100 mM sodium phos-
phate buffer (pH 7.0). The reaction was initiated by addition of 0.2 mg of
mtFabH. After incubation at 37C for 60 min, the reaction was
quenched and reduced by adding 500 ml of 5 mg/ml NaBH4 in
100 mM K2HPO4, 100 mM KCl, 30% tetrahydrofuran and keeping it
at 37C for 20–30 min. The radiolabeled 3-ketoacyl-CoA thioester
product was reduced to the corresponding acyl-1,2-diols, extracted
with 500 ml of toluene, and quantitated using a liquid scintillationChemistry & Biology 14,counter. Alkyl-CoA disulfides were either preincubated with the ec-
FabH enzymes for 15 min or added at the same time as the substrates.
The IC50 (concentration of inhibitor at which 50% inhibition of FabH is
achieved) was determined by duplicate assays with a minimum of six
concentrations of inhibitor. The IC50 values were calculated with Grafit
4.012 (Erithacus Software).
Stopped-Flow Fluorimetry
A microvolume stopped-flow reaction analyzer, the SF-61 DX2 Double
Mixing Stopped Flow system (Hi-Tech Scientific), equipped with a fluo-
rescence detector and a thermostated cell, was used to monitor the
changes in Trp fluorescence due to the reaction of ecFabH with MeSS-
CoA (1). Measurements were carried out in 50 mM phosphate buffer
(pH 7.4) at 25C. The excitation wavelength was set at 290 nm, and
the progress of the reaction was monitored by measuring the changes
in Trp fluorescence emission through a 320 nm cutoff filter. Interaction
of ecFabH with 1 resulted in two distinct changes in Trp fluorescence
emission: an initial fast decrease followed by a slow increase. Both fast
and slow phases were analyzed separately using SigmaPlot 8.0
(SPSS) for Windows. For the fast step, a decrease in the Trp fluores-
cence emission was fitted to a single exponential equation, Ft = A +
B e(kobs)t, where Ft is the fluorescence at time t, A is an offset, B is
the amplitude, and kobs is the pseudo-first-order rate constant. The
dependence of kobs on [1] was fit to the hyperbolic equation kobs =
klim*[1]/(K0.5 + [1]), where klim is the limiting rate constant of the first
step and K0.5 is the concentration of MeSSCoA (1) at half-saturation.
For the slow second step, the observed increase in Trp fluorescence
emission was fit to the equation Ft = A +B (1 ekobst), where Ft is fluo-
rescence emission at time t, A is an offset, and B is the amplitude.
Values of kobs were plotted against reactant concentration and the
linear equation was fit to the data to obtain the kslow value.
Time-Dependent Inhibition
The time course for inactivation of ecFabH by a range of MeSSCoA (1)
concentrations (1–50 mM) was conducted by incubation in 50 mM so-
dium phosphate buffer (pH 7.4) at room temperature and withdrawing
samples for assay at specific time points. Activity was expressed as
a fraction of activity remaining relative to a control experiment carried
out in the absence of inhibitor. Time dependencies of activity of FabH
incubated with 1 were analyzed using SigmaPlot 8.0 software (SPSS)
for Windows. A double exponential equation (At = A0 e
k0obst +
B0 e
kobst) was fitted to the observed decrease in ecFabH activity
with time, where (A0 + B0) and At are activities of FabH at times zero
and t, and k0obs and kobs are the observed rate constants for the fast
and slow loss of ecFabH activity, respectively. The values of kobs
were plotted versus [1] and fit by a hyperbolic equation, kobs =
ki2*[1]/(Ki + [1]), where Ki is the dissociation constant of the FabH-1
complex and ki2 is the rate constant of the slow FabH inhibition step.
The rate constant for the fast inhibition step, ki1, was estimated from
the values of kobs at saturation (10 and 50 mM of MeSSCoA).
Reversibility Tests
A solution of ecFabH (500 ml of a 1.3 mM solution in 50 mM sodium
phosphate buffer [pH 7.4]) was preincubated with MeSSCoA (1)
(6.6 ml of a 10 mM solution in water; ratio of inhibitor to enzyme,
100:1) for 30 min at room temperature. A control solution containing
the ecFabH enzyme in buffer and 6.6 ml of water with no inhibitor
was treated in the same manner. Two aliquots from each solution
(2 ml each) were withdrawn, and the ecFabH activity was determined
under standard assay conditions. The remaining enzyme solutions
were dialyzed against 50 mM sodium phosphate buffer (pH 7.4) for
12 hr at 4C and the enzyme activity was determined. The enzyme
solutions were then treated with DTT (10 mM final concentration) for
30 min at room temperature, dialyzed against 50 mM sodium phos-
phate buffer (pH 7.4) for 3 hr at 4C, and the enzyme activity was
determined under standard conditions (see above).513–524, May 2007 ª2007 Elsevier Ltd All rights reserved 521
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The extent of acylation of ecFabH was determined by measuring the
transfer of a radiolabeled acetyl group from [14C]acetyl-CoA to ec-
FabH. The standard 20 ml reaction mixture contained 50 mM sodium
phosphate buffer (pH 7.4) and ecFabH (0.2 nmol of monomer,
10 mM), and the acylation was initiated by adding [14C]acetyl-CoA
(2 nmol, 100 mM). The mixture was incubated at room temperature
and aliquots were removed at intervals over a 10 min period. For
each sample, the reaction was stopped by addition of 10% trichloro-
acetic acid and analyzed in the standard way using liquid scintillation
counting. A plot of the amount of radiolabeled protein versus time
was constructed and used to estimate ka1 and ka2.
Acylation Assay of an50% Active ecFabH-MeSSCoA Complex
ecFabH (0.2 nmol of monomer, 10 mM) was incubated with MeSSCoA
(10 nmol, 500 mM) in 50 mM sodium phosphate buffer (pH 7.4) at room
temperature for 2 min. An aliquot of this partially inhibited ecFabH
(5 mM) MeSSCoA mixture was incubated with [14C]acetyl-CoA
(50 mM) and malonyl-ACP (4 mM), and shown in a standard FabH assay
[10, 33] to reproducibly retain approximately 50% of the activity of the
native protein. An acylation assay of this same partially inhibited
ecFabH (5 mM) MeSSCoA was simultaneously carried out over a range
of [14C]acetyl-CoA concentrations (50–500 mM). These two assays
were repeated multiple times with different enzyme-acetyl-CoA ratios
with the same result that the overall rate for the catalytic process
(>0.016 s1) was approximately 240-fold higher than the acylation
rate (ka = 6.6 3 10
5 s1).
X-Ray Structure Determination of the ecFabH-MeSSCoA (1)
Complexes
Crystals of ecFabH and the ecFabH-MeSSCoA complex were
obtained by the hanging drop method at room temperature. For the
former, drops composed of equal volumes of a solution of 15 mg/ml
ecFabH in 20 mM Tris (pH 7.4) and a reservoir solution (0.1 M sodium
HEPES [pH 7.5], 1.6–1.9 M ammonium sulfate, 2% PEG-400) were
equilibrated against the reservoir solution. Optimal crystals of the ec-
FabH-MeSSCoA complex were obtained by mixing 2.2 ml of protein-
inhibitor complex solution with 2.2 ml of reservoir solution (0.1 M
sodium HEPES [pH 7.0], 1.7 M ammonium sulfate, 2% PEG-400)
and equilibrating the drops against the reservoir. The protein-inhibitor
complex was prepared by mixing MeSSCoA (1) (10 mM solution in wa-
ter) with ecFabH enzyme solution (10 mg/ml in 20 mM sodium HEPES
[pH 7.2]) at a molar ratio of protein:inhibitor = 1:4 and incubated for sev-
eral hours at 4C. Conditions used for crystallization of both ecFabH
and the ecFabH-MeSSCoA (1) complex are similar to those described
for native crystals [23], and the lattice of the complex is closely similar
to that of the native crystals (a = 64.38, b = 82.04, c = 121.67, P212121,
two monomers per asymmetric unit). Crystals of the ecFabH-MeSS-
CoA complex diffract to 2.0 A˚ resolution. Crystals of ecFabH stabilized
in 0.1 M sodium HEPES (pH 7.5), 2.2 M ammonium sulfate, 2% PEG-
400 were soaked for 20–24 hr in a cold room with the same solution
containing either 0.16 mM or 1.7 mM MeSSCoA. These crystals also
diffracted to about 2 A˚ resolution.
X-ray data were collected at 100K using a Molecular Structure
Corporation (MSC) X-Stream Cryogenic Crystal Cooler system and
an R-Axis IV2+ image plate detector on a Rigaku MicroMax-007
X-ray source equipped with MSC Varimax confocal optics operating
at 40 kV and 20 mA. The data set was processed with the MSC
d*TREK software program. Prior to data collection, crystals were first
washed in cryoprotectant solution containing 1.6 M ammonium sulfate
(for the complex) or 2.2 M ammonium sulfate (for preformed, soaked
crystals), 2% PEG-400, 0.5 mM methyl-CoA disulfide, 100 mM sodium
HEPES (pH 7.0), 5% glycerol, followed by transfer to similar solutions
with 12% and 17% glycerol.
An initial model of the unliganded ecFabH dimer (RCSB accession
number 1HND) was placed in the unit cell of the ecFabH-MeSSCoA
crystal with rigid body refinement as implemented in CNS version
1.0. This model was refined iteratively by cycles of simulated annealing522 Chemistry & Biology 14, 513–524, May 2007 ª2007 Elsevwith torsion angle dynamics as implemented in CNS version 1.0
coupled with TLS [49] and positional refinement in REFMAC5 [50],
followed by manual rebuilding into 2 mFo  dFc, mFo  dFc, and
2 mFo  dFc composite omit maps using the graphics programs
TOM [51, 52] and Xfit [53]. In the final stages of the refinement, 200
water molecules were added to the structure based on the presence
of peaks with intensities of >3s in an mFo  dFc difference Fourier
map. During refinement, residue geometries were monitored via PRO-
CHECK [54] and WHATCHECK [55], whereas nonbonded contacts
were monitored via PROBE [56] as integrated with Xfit. Model co-
ordinate errors were estimated via Cruikshank’s diffraction precision
indicator as implemented in SFCHECK [57].
Supplemental Data
Supplemental Data include four figures and one table and are available
at http://www.chembiol.com/cgi/content/full/14/5/513/DC1/.
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